Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

Christopher Em Griffiths; Kim Papp; Michael Song; Megan Miller; Yin You; Yaung‐Kaung Shen; Chenglong Han; Andrew Blauvelt

doi:10.1080/09546634.2020.1782817

Back

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

Article 2020 en

Related publications

Article2018

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Christopher Em Griffiths, Kim Papp, Alexa B. Kimball, B. Randazzo, Michael Song, Shu Li, Yaung‐Kaung Shen, Andrew Blauvelt

Letter2023

Immunogenicity and pharmacokinetics of guselkumab among patients with moderate‐to‐severe psoriasis in VOYAGE‐1 and VOYAGE‐2

April W. Armstrong, Kilian Eyerich, Curdin Conrad, Yihong Zhu, Ya‐Wen Yang, Megan Miller, Yin You, Yaung‐Kaung Shen, Peter Foley, Christopher Em Griffiths, Bruce Strober

Article2019

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

Kristian Reich, Christopher Em Griffiths, Kenneth B. Gordon, Kim Papp, Michael Song, B. Randazzo, Shu Li, Yaung‐Kaung Shen, Chenglong Han, Alexa B. Kimball, April W. Armstrong, Peter Foley, Andrew Blauvelt

Article2017

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase <scp>III VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies

Kenneth B. Gordon, Andrew Blauvelt, Peter Foley, Michael Song, Yasmine Wasfi, B. Randazzo, Yaung‐Kaung Shen, Yin You, Christopher Em Griffiths

Article2018

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized <scp>VOYAGE</scp> 1 trial

Kim Papp, Andrew Blauvelt, Alexa B. Kimball, Chenglong Han, B. Randazzo, Yasmine Wasfi, Yaung‐Kaung Shen, S. Li, Christopher Em Griffiths

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

Abstract

Discussion(0)

Related publications

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Immunogenicity and pharmacokinetics of guselkumab among patients with moderate‐to‐severe psoriasis in VOYAGE‐1 and VOYAGE‐2

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase <scp>III VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized <scp>VOYAGE</scp> 1 trial